Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kangkagate C is active.

Publication


Featured researches published by Kangkagate C.


American Heart Journal | 1995

Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results.

Mahanonda N; Bhuripanyo K; Kangkagate C; Kanchana Wansanit; Bang-on Kulchot; Koonlawee Nademanee; Chaithiraphan S

The objective of this investigation was the assessment of the response rate of oral atenolol in patients with vasovagal syncope after 1 month of treatment. We randomized into two groups all patients referred to our unit who had had at least one episode of syncope or two episodes of presyncope 1 month before presentation and had a positive isuprel Tilt Table Test (TTT). Group 1 (Gr 1) received oral atenolol, and group 2 (Gr 2) received placebo medication. After a 1-month period patients were reassessed for degree of their symptoms and underwent repeated TTT. Forty-two patients were enrolled in the study. Gr 1 and Gr 2 were comparable in age (38 +/- 13 years vs 43 +/- 14 years, p = 0.216 and sex (male/female = 6:15 vs 10:11, p = 0.204). The severity of attack was similar in both groups. Eight patients in Gr 1 and six patients in Gr 2 had mitral valve prolapse (p = 0.5). No significant differences were seen in systolic blood pressure (122 +/- 17 vs 117 +/- 16 mmHg, p = 0.334), diastolic blood pressure (70 +/- 11 vs 72 +/- 11 mm Hg, p = 0.677), and heart rate (79 +/- 12 vs 79 +/- 13, p = 0.98) between the two groups. The response rates (negative TTT) after 1 month of treatment were 62% versus 5% (p = 0.0004) in the atenolol and control group, respectively. Moreover, patients who received atenolol reported feeling better compared with those who received placebo (71% vs 29%, p = 0.02). In conclusion, atenolol significantly improved symptoms of patients with vasovagal syncope.(ABSTRACT TRUNCATED AT 250 WORDS)


Pediatric Cardiology | 2003

Immunoglobulin failure and retreatment in Kawasaki disease

Kritvikrom Durongpisitkul; Jarupim Soongswang; Duangmanee Laohaprasitiporn; Apichart Nana; C. Prachuabmoh; Kangkagate C

Several cases of Kawasaki disease (KD) were unresponsive to the initial treatment with intravenous immunoglobulin (IVIG). We retrospectively analyzed all children admitted with KD to determine the occurrence and variables associated with the initial IVIG treatment failure. All patients who fulfilled the criteria for KD and were treated with a single dose (2 g/kg) of IVIG between January 1995 and August 2001 were enrolled. An analysis of the patients who had initially failed to respond to IVIG was performed. A total of 120 patients were enrolled during the study period. There were 68 boys (56.7%). Fourteen patients (11.6%) were found to be unresponsive to initial IVIG treatment. Patients who were anemic (Hb<10 G/DL), HAD A HIGH NEUTROPHIL COUNT (> 75%), a high band count, and low albumin were at risk of failure to respond to a single dose of IVIG. We found no correlation among age, gender, days since starting IVIG treatment, and erythrocyte sedimentation rate (ESR) with failure of the initial IVIG treatment. There were 12 patients (10%) who developed coronary artery aneurysms. The failure of a single dose of IVIG treatment occured in up to 11.6% of our Kawasaki patients. We found that low hemoglobin (<10 G/DL), HIGH NEUTROPHIL COUNT (> 75%), high band count, and a low albumin were associated with the requirement for retreatment with a second dose of IVIG.


Pediatric Cardiology | 2005

Cardiac Troponin T: A Marker in the Diagnosis of Acute Myocarditis in Children

Jarupim Soongswang; Kritvikrom Durongpisitkul; Apichart Nana; D. Laohaprasittiporn; Kangkagate C; K. Punlee; N. Limpimwong

This study was conducted to assess the use of serum cardiac troponin T (cTnT) level as a noninvasive indicator to diagnose acute myocarditis in children. Noninvasive conventional methods often fail to diagnose myocarditis, A median cTnT level of 0.088 ng/ml (0.04–3.11) was reported in pediatric patients with acute myocarditis in our previous study. Hence, we attempted to determine the cutfoff level of cTnT to diagnose acute myocarditis in children. Pediatric patients with clinically suspected myocarditis or dilated cardiomyopathy (DCM) and a control group were recruited. History, physical examination, elctrocardiogram, chest roentgenogram, echocardiogram, cTnT level, and/or endomyocardial biopsy and clinical course were studied. The gold standard to diagnose acute myocarditis was endomyocardial biopsy proved according to the Dallas criteria and/or recovery from cardiovascular problems within 6 months of follow-up. Forty-three patients were admitted due to cardiovascular problems from primary myocardial dysfunction. Twenty-four patients were diagnosed as acute myocarditis (group 1), 19 were idiopathic chronic DCM (group 2), and 21 patients had moderate to large ventricular septal defect and congestive heart failure (group 3). Median cTnT level was statistically higher in (group 1) compared to groups 2 and 3. Ejection fraction (EF) and left ventricular end diastolic dimension (LVEDd) z score of acute myocarditis were 38.5% (range, 21–67) and 1.3 (range, −0.8–3.0), respectively, which were significantly better than DCM [28.0% (range, 17–45) and 6.0 (range, 2.0–10.0)]. The cutoff point of cTnT level to diagnose acute myocarditis was 0.052 ng/ml (sensitivity, 71%; specificity, 86%). cTnT level, EF, and LVEDd z score did not predict short-term outcomes of patients. In acute myocarditis, cTnT level and EF were significantly higher and LVEDd z score was significantly lower than in DCM. However, the three parameters had no significant effect on outcomes of the patients. Our data show that cardiac a cTnT level of 0.052 ng/ml is an appropriate cutoff point for the diagnosis of acute myocarditis.


Pediatric Cardiology | 2002

Comparison of Atrial Septal Defect Closure Using Amplatzer Septal Occluder with Surgery

Kritvikrom Durongpisitkul; Jarupim Soongswang; Duangmanee Laohaprasitiporn; Apichart Nana; Somchai Sriyoschati; S. Ponvilawan; Thaworn Subtaweesin; Kangkagate C

Our study reports the results of a comparison of closure of atrial septal defect (ASD) surgically with transcatheter closure using the Amplatzer septal occluder. Patients having an ASD and a surgical closure or transcatheter closure between January 1999 and July 2000 were selected. There were 103 patients who had ASD. All 64 patients in group 1 (surgery) had a successful operation, with only 2 patients with a mild residual shunt. There were 39 patients enrolled for transcatheter closure of the ASD (group 2). Four patients were excluded initially. The median age for group 1 was 25 years (range 2.3-64 years) compared to 11.7 years (range 2-69 years) in group 2 (p= 0.035). In group 1, the mean ASD diameter measured was 28.4 ± 10.2 mm compared to 23.4 ± 5.7 mm in group 2 (p = 0.003). In 29 patients, devices were deployed with sizes from 10 mm to 30 mm (median 24 mm). Three patients were excluded because a larger device (>?30 mm) was not available and devices were not successfully deployed in another 3 patients. One patient had a device embolized into the right ventricle (surgical removal and closure of the ASD). Complications occurred in 13 patients in group 1 and 4 patients in group 2. Complete occlusion occurred in 27 of 28 group 2 patients (96.4%) during the follow-up period (10.2 ± 5.4 months). The Amplatzer septal occluder is a new device for closure of different-sized ASDs. The intermediate-term follow-up demonstrated excellent closure results. The benefit for each patient was demonstrated in less morbidity and less time spent in the hospital.


Pediatric Cardiology | 2002

Cardiac troponin T: its role in the diagnosis of clinically suspected acute myocarditis and chronic dilated cardiomyopathy in children.

Jarupim Soongswang; Kritvikrom Durongpisitkul; S. Ratanarapee; Wattana Leowattana; A. Nana; D. Laohaprasitiporn; S. Akaniroj; N. Limpimwong; Kangkagate C

AbstractThis study was conducted to assess the use of the serum cardiac troponin T (cTnT) level as a noninvasive indicator to differentiate acute myocarditis and chronic dilated cardiomyopathy in pediatric patients. Myocarditis and dilated cardiomyopathy are clinically difficult to differentiate. Endomyocardial biopsy proved to be quite useful. However, the nature of the procedure—invasiveness, time-consuming, and limited sensitivity—caused some concerns, especially in pediatric patients. Hence, we attempted to find an alternative method that could give a prompt diagnosis of acute myocarditis. Twenty cases with clinically suspected myocarditis or dilated cardiomyopathy and a control group of 21 cases with moderate left-to-right shunt and congestive heart failure were recruited. History, physical examination, electrocardiogram, chest roentgenogram, echocardiogram, cTnT, creatine kinase MB isoenzyme (CK-MB mass), and/or endomyocardial biopsy were compared. The gold standard used to diagnose myocarditis is endomyocardial biopsy (Dallas criteria) and/or recovery from cardiovascular problems within 6 months of follow-up. Ten patients were diagnosed as having myocarditis (group 1) and 10 with chronic dilated cardiomyopathy (group 2). The control group of 21 cases was designated as group 3. The median serum cTnT levels were 0.088 (0.04–3.11), 0.010 (0.010–0.990), and 0.010 (0.010–0.550) ng/ml in groups 1, 2, and 3, respectively. The mean CK-MB mass level for groups, 1, 2, and 3 were 18.35 (7.14–70.00), 4.80 (0.54–108.00), and 2.26 (0.95–7.06) ng/ml. The study showed that both the cTnT and CK-MB mass levels were significantly higher in group 1 than either group 2 or group 3. Histopathology was studied in 9 cases. In 2 of 5 cases and in all 4 cases in group 1 and group 2 histopathology was pathologically proved. Levels of cTnT and CK-MB were significantly higher for myocarditis than for dilated cardiomyopathy and left-to-right shunt with CHF. Further study is needed to assess the optimum cTnT level for differentiating both conditions.


American Journal of Cardiology | 2002

One-year outcome after radiofrequency catheter ablation of symptomatic ventricular arrhythmia from right ventricular outflow tract

Rungroj Krittayaphong; Charn Sriratanasathavorn; Bhuripanyo K; Raungratanaamporn O; Jaruprim Soongsawang; Burin Khaosa-ard; Kangkagate C

Although ventricular premature complexes (VPCs) in patients without structural heart disease are benign, many patients experience disabling symptoms. Many patients need long-term medication, which is often ineffective and may have adverse effects. Radiofrequency catheter ablation (RFCA) may be an alternative treatment. RFCA was performed in 33 patients with severely symptomatic VPCs that were refractory to medication. Mean VPCs were 23,987 +/- 2,077 beats/24 hours. Twenty-four-hour ambulatory electrocardiographic monitoring, quality of life, and symptoms were assessed at a screening visit and 1 and 12 months after RFCA. RFCA was successfully performed in 32 patients (97%). This resulted in a significant improvement in symptoms, severity of ventricular arrhythmia, and quality of life at 1 and 12 months after the procedure. There were no major complications related to the procedure. Eight patients (24%) had residual arrhythmia. Five of them underwent repeated ablation with successful results. Thus, catheter ablation is a safe and effective treatment for symptomatic ventricular arrhythmia from the right ventricular outflow tract. It also improves the quality of life. Catheter ablation is a viable alternative to drugs in the presence of disabling symptoms.


Pediatric Cardiology | 2005

The Effect of Coenzyme Q10 on Idiopathic Chronic Dilated Cardiomyopathy in Children

Jarupim Soongswang; C. Sangtawesin; Kritvikrom Durongpisitkul; Duangmanee Laohaprasitiporn; Apichart Nana; K. Punlee; Kangkagate C

The objective of this study was to assess the effect of coenzyme Q10 (CoQ10) as supplementation to conventional antifailure drugs on quality of life and cardiac function in children with chronic heart failure due to dilated cardiomyopathy (DCM). The study was an open-label prospective study performed in two of the largest pediatric centers in Thailand from August 2000 to June 2003. A total of 15 patients with idiopathic chronic DCM were included, with the median age of 4.4 years (range, 0.6-16.3). Presenting symptoms were congestive heart failure in 12 cases (80%), cardiogenic shock in 2 cases (13.3%), and cardiac arrhythmia in 1 case (6.7%). Sixty-one percent of patients were in the New York Heart Association functional class 2 (NYHA 2), 31% in NYHA 3, and 8% in NYHA 4. Cardiothoracic ratio from chest x-ray, left ventricular ejection fraction, and left ventricular end diastolic dimension in echocardiogram were 0.62 (range, 0.55-0.78), 30% (range, 20-40), and 5.2 cm (range, 3.8-6.5), respectively. CoQ10 was given at a dosage of 3.1 ? 0.6 mg/kg/day for 9 months as a supplementation to a fixed amount of conventional antifailure drugs throughout the study. At follow-up periods of 1, 3, 6, and 9 months, NYHA functional class was significantly improved, as was CT ratio and QRS duration at 3 and 9 months follow-up with CoQ10 when compared to the baseline and post-discontinuation of CoQ10 at 9 months (range, 4.8-10.8). However, when multiple comparisons were taken into consideration, there was no statistical significant improvement. In addition to the conventional antifailure drugs, CoQ10 may improve NYHA class and CT ratio and shorten ventricular depolarization in children with chronic idiopathic DCM.


Journal of The American Society of Echocardiography | 1995

Multivariate analysis in the prediction of left atrial thrombi in patients with mitral stenosis

Yonguth Sahasakul; Chaithiraphan S; Panchavinnin P; Naris Srivanasont; Payonk Jootar; Damras Trisukosol; Raungratanaamporn O; Chotinaiwattarakul C; Kangkagate C

The prediction of left atrial thrombi based on clinical and investigative data was evaluated prospectively in 100 consecutive patients with significant mitral stenosis. Nineteen patients had left atrial thrombi by surgical findings. Age, atrial fibrillation, and mitral valve area were the variables that predicted the presence of left atrial thrombus, whereas sex, dimension of left atrium, history of systemic embolism, history of previous mitral valvuloplasty, and associated significant mitral regurgitation were not. Patients with atrial fibrillation have a sixfold increase in risk of atrial thrombi compared with patients in sinus rhythm. Transthoracic echocardiography detected 11 (58%) of 19 and transesophageal echocardiography detected 17 (89%) of 19 thrombi found by surgical inspection. Multivariate analysis showed that age and atrial fibrillation were the best predictors of left atrial thrombus. In general clinical practice, these variables could be used to predict left atrial thrombi in patients with mitral stenosis. However, in certain situations such as prior percutaneous balloon mitral valvuloplasty or prior electrical cardioversion, transesophageal echocardiographic examination should be used for high accuracy in the detection of extent and location of left atrial thrombi.


Journal of Obstetrics and Gynaecology Research | 2005

Predicting fetal anemia by using reference centile charts for liver length, spleen perimeter and umbilical vein maximum flow velocity in Thai fetuses throughout gestation

Saifon Chawanpaiboon; Vitaya Titapant; Anuwat Sutantawibul; Sujin Kanokpongsakdi; Kangkagate C

Aim: To create reference centile charts for liver length, spleen perimeter and umbilical vein maximum flow velocity (UVVmax) in Thai fetuses in order to predict fetal anemia in Thai fetuses.


Journal of the Medical Association of Thailand Chotmaihet thangphaet | 2003

A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation.

Rungroj Krittayaphong; Raungrattanaamporn O; Bhuripanyo K; Charn Sriratanasathavorn; Pooranawattanakul S; Punlee K; Kangkagate C

Collaboration


Dive into the Kangkagate C's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge